Idiopathic ventricular fibrillation

Electrical Diseases of the Heart

Volumn 1, Issue , 2013, Pages 629-646

  Viskin, Sami ^a   Adler, Arnon ^a   Belhassen, Bernard ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Early repolarization; Short QT syndrome; Sudden death; Ventricular fibrillation

Indexed keywords

EID: 84902951886     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4471-4881-4_36     Document Type: Chapter

References (119)

1. Dock W. Transitory ventricularfibrillation as a cause of syncope and its prevention by quinidine sulfate. Am Heart J. 1929;4:709-14.
2. Belhassen B, Shapira I, Shoshani D, Paredes A, Miller H, Laniado S. Idiopathic ventricularfibrillation: inducibility and beneficial effects of class I antiarrhythmic agents. Circulation. 1987;75: 809-16.
3. Viskin S, Belhassen B. Idiopathic ventricularfibrillation. Am Heart J. 1990;120:661-71.
4. Leenhardt A, Glaser E, Burguera M, Nurnberg M, Maison-Blanche P, Coumel P. Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. Circulation. 1994; 89:206-15.
5. Viskin S, Lesh M, Eldar M, et al. Mode of onset of malignant ventricular arrhythmias in idiopathic ventricularfibrillation. J Cardiovasc Electrophysiol. 1997;8:1115-20.
6. Haissaguerre M, Extramiana F, Hocini M, et al. Mapping and ablation of ventricularfibrillation associated with long-QT and Brugada syndromes. Circulation. 2003;108:925-8.
7. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J. 1957;54:59-68.
8. Romano C, Gemme G, Pongiglione R. Aritmie cardiache rare dell'eta pediatrica. Clin Pediatr. 1963;45:656-83.
9. Ward OC. A new familial cardiac syndrome in children. J Ir Med Assoc. 1964;54:103-6.
10. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc D, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year followup of 21 patients. Circulation. 1995;91:1512-19.
11. Aponte G. The enigma of "Bangungut". Ann Intern Med. 1960;52:1258-63.
12. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992;20:1391-6.
13. Viskin S, Fish R, Eldar M, et al. Prevalence of the Brugada sign in idiopathic ventricularfibrillation and healthy controls. Heart. 2000;84:31-6.
14. Nademanee K, Veerakul G, Nimmannit S, et al. Arrhythmogenic marker for the sudden unexpected death syndrome in Thai men. Circulation. 1997;96:2595-600.
15. Gussak I, Brugada P, Brugada J, et al. Idiopathic short QT interval: a new clinical syndrome? Cardiology. 2000;94:99-102.
16. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: a familial cause of sudden death. Circulation. 2003;108:965-70.
17. Schimpf R, Bauersfeld U, Gaita F, Wolpert C. Short QT syndrome: successful prevention of sudden cardiac death in an adolescent by implantable cardioverter-defibrillator treatment for primary prophylaxis. Heart Rhythm. 2005;2:416-17.
18. Viskin S, Zeltser D, Ish-Shalom M, et al. Is idiopathic ventricularfibrillation a short QT syndrome? Comparison of QT intervals of patients with idiopathic ventricularfibrillation and healthy controls. Heart Rhythm. 2004;1:587-91.
19. Haissaguerre M, Derval N, Sacher F, et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med. 2008;358:2016-23.
20. Nam GB, Kim YH, Antzelevitch C. Augmentation of J waves and electrical storms in patients with early repolarization. N Engl J Med. 2008;358:2078-9.
21. Rosso R, Kogan E, Belhassen B, et al. J-point elevation in survivors of primary ventricularfibrillation and matched control subjects incidence and clinical significance. J Am Coll Cardiol. 2008;52:1231-8.
22. Antzelevitch C, Yan GX. J wave syndromes. Heart Rhythm. 2010;7:549-58.
23. Gussak I, Bjerregaard P. Short QT syndrome-5 years of progress. J Electrocardiol. 2005;38:375-7.
24. Viskin S. The QT, interval: too long, too short or just right. Heart Rhythm. 2009;6:711-15.
25. Templin C, Ghadri JR, Rougier JS, et al. Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6). Eur Heart J. 2011;32:1077-88.
26. Fujiki A, Sugao M, Nishida K, et al. Repolarization abnormality in idiopathic ventricularfibrillation: assessment using 24-hour QT-RR and QaT-RR relationships. J Cardiovasc Electrophysiol. 2004; 15:59-63.
27. Sugao M, Fujiki A, Sakabe M, et al. New quantitative methods for evaluation of dynamic changes in QT interval on 24 hour Holter ECG recordings: QT interval in idiopathic ventricularfibrillation and long QT syndrome. Heart. 2006;92:201-7.
28. Alders M, Koopmann TT, Christiaans I, et al. Haplotype-sharing analysis implicates chromosome 7q36 harboring DPP6 in familial idiopathic ventricularfibrillation. Am J Hum Genet. 2009;84:468-76.
29. Allan WC, Timothy K, Vincent GM, Palomaki GE, Neveux LM, Haddow JE. Long QT syndrome in children: the value of rate corrected QT interval and DNA analysis as screening tests in the general population. J Med Screen. 2001;8:173-7.
30. Ghosh S, Cooper DH, Vijayakumar R, et al. Early repolarization associated with sudden death: insights from noninvasive electrocardiographic imaging. Heart Rhythm. 2010;7:534-7.
31. Viskin S, Rosso R, Halkin A. Making sense of early repolarization. Heart Rhythm. 2012;9:566-9.
32. Watanabe H, Nogami A, Ohkubo K, et al. Electrocardiographic characteristics and SCN5A mutations in idiopathic ventricularfibrillation associated with early repolarization. Circ Arrhythm Electrophysiol. 2011;4:874-81.
33. Belhassen B, Viskin S. Idiopathic ventricular tachycardia andfibrillation. J Cardiovasc Electrophysiol. 1993;4:356-68.
34. Haissaguerre M, Shah DC, Jais P, et al. Role of Purkinje conducting system in triggering of idiopathic ventricularfibrillation. Lancet. 2002;359:677-8.
35. Haissaguerre M, Shoda M, Jais P, et al. Mapping and ablation of idiopathic ventricularfibrillation. Circulation. 2002;106:962-7.
36. Sinha AM, Schmidt M, Marschang H, et al. Role of left ventricular scar and Purkinje-like potentials during mapping and ablation of ventricularfibrillation in dilated cardiomyopathy. Pacing Clin Electrophysiol. 2009;32:286-90.
37. Arnar DO, Bullinga JR, Martins JB. Role of the Purkinje system in spontaneous ventricular tachycardia during acute ischemia in a canine model. Circulation. 1997;96:2421-9.
38. Ideker RE, Kong W, Pogwizd S. Purkinjefibers and arrhythmias. Pacing Clin Electrophysiol. 2009;32:283-5.
39. Nogami A. Purkinje-related arrhythmias part ii: polymorphic ventricular tachycardia and ventricularfibrillation. Pacing Clin Electrophysiol. 2011;34:1034-49.
40. Berenfeld O, Jalife J. Purkinje-muscle reentry as a mechanism of polymorphic ventricular arrhythmias in a 3-dimensional model of the ventricles. Circ Res. 1998;82:1063-77.
41. Burashnikov A, Antzelevitch C. Late-phase 3 EAD. A unique mechanism contributing to initiation of atrialfibrillation. Pacing Clin Electrophysiol. 2006;29:290-5.
42. Antzelevitch C, Bernstein MJ, Feldman HN, Moe GK. Parasystole, reentry, and tachycardia: a canine preparation of cardiac arrhythmias occurring across inexcitable segments of tissue. Circulation. 1983;68:1101-15.
43. Viskin S, Belhassen B. Polymorphic ventricular tachyarrhythmias in the absence of organic heart disease. Classification, differential diagnosis and implications for therapy. Prog Cardiovasc Dis. 1998;41:17-34.
44. Haissaguerre M, Sacher F, Nogami A, et al. Characteristics of recurrent ventricularfibrillation associated with inferolateral early repolarization role of drug therapy. J Am Coll Cardiol. 2009;53:612-19.
45. Pasquie JL, Sanders P, Hocini M, et al. Fever as a precipitant of idiopathic ventricularfibrillation in patients with normal hearts. J Cardiovasc Electrophysiol. 2004;15:1271-6.
46. Yan GX, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation. 1998;98:1928-36.
47. Castro Hevia J, Antzelevitch C, Tornes Barzaga F, et al. Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricularfibrillation in patients with the Brugada syndrome. J Am Coll Cardiol. 2006;47:1828-34.
48. Abe A, Ikeda T, Tsukada T, et al. Circadian variation of late potentials in idiopathic ventricularfibrillation associated with J waves: insights into alternative pathophysiology and risk stratification. Heart Rhythm. 2010;7:675-82.
49. Nam GB, Ko KH, Kim J, et al. Mode of onset of ventricularfibrillation in patients with early repolarization pattern vs. Brugada syndrome. Eur Heart J. 2009;31:330-9.
50. Rosso R, Glikson E, Belhassen B, et al. Distinguishing "benign" from "malignant early repolarization": The value of the ST-segment morphology. Heart Rhythm. 2012;9(2):225-9.
51. Champagne J, Geelen P, Philippon F, Brugada P. Recurrent cardiac events in patients with idiopathic ventricularfibrillation, excluding patients with the Brugada syndrome. BMC Med. 2005;3:1.
52. Belhassen B, Pelleg A, Miller HI, Laniado S. Serial electrophysiological studies in a young patient with recurrent ventricularfibrillation. PACE. 1981;4:92-9.
53. Belhassen B, Viskin S, Fish R, Glick A, Setbon I, Eldar M. Effects of electrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricularfibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol. 1999;10:1301-12.
54. Gaita F, Giustetto C, Bianchi F, et al. Short QT syndrome: pharmacological treatment. J Am Coll Cardiol. 2004;43:1494-9.
55. Brugada P, Geelen P, Brugada R, Mont L, Brugada J. Prognostic value of electrophysiologic investigations in Brugada syndrome. J Cardiovasc Electrophysiol. 2001;12:1004-7.
56. Shimada M, Miyazaki T, Miyoshi S, et al. Sustained monomorphic ventricular tachycardia in a patient with Brugada syndrome. Jpn Circ J. 1996;60:364-70.
57. Viskin S, Belhassen B. Clinical problem solving: when you only live twice. N Engl J Med. 1995; 332:1221-5.
58. Boersma LV, Jaarsma W, Jessurun ER, Van Hemel NH, Wever EF. Brugada syndrome: a case report of monomorphic ventricular tachycardia. Pacing Clin Electrophysiol. 2001;24:112-15.
59. Dinckal MH, Davutoglu V, Akdemir I, Soydinc S, Kirilmaz A, Aksoy M. Incessant monomorphic ventricular tachycardia during febrile illness in a patient with Brugada syndrome: fatal electrical storm. Europace. 2003;5:257-61.
60. Mok NS, Chan NY, Chiu AC. Successful use of quinidine in treatment of electrical storm in Brugada syndrome. Pacing Clin Electrophysiol. 2004;27:821-3.
61. Brugada P, Green M, Abdollah H, Wellens HJJ. Significance of ventricular arrhythmias initiated by programmed ventricular stimulation: the importance of the type of ventricular arrhythmia induced and the number of premature stimuli required. Circulation. 1984;69:87-92.
62. Morady F, DiCarlo L, Baerman J, de Buitleir M. Comparison of coupling intervals that induce clinical and nonclinical forms of ventricular tachycardia during programmed stimulation. Am J Cardiol. 1986;57:1269-73.
63. Stevenson WG, Brugada P, Waldecker B, Zehender M, Wellens HJ. Can potentially significant polymorphic ventricular arrhythmias initiated by programmed stimulation be distinguished from those that are nonspecific? Am Heart J. 1986;111:1073-80.
64. Viskin S, Rogowski O. Asymptomatic Brugada syndrome: a cardiac ticking time-bomb? Europace. 2007;9:707-10.
65. Viskin S, Rosso R, Rogowski O, Belhassen B. The "short-coupled" variant of right ventricular outflow ventricular tachycardia: a not-so-benign form of benign ventricular tachycardia? J Cardiovasc Electrophysiol. 2005;16:912-16.
66. Noda T, Shimizu W, Taguchi A, et al. Malignant entity of idiopathic ventricularfibrillation and polymorphic ventricular tachycardia initiated by premature extrasystoles originating from the right ventricular outflow tract. J Am Coll Cardiol. 2005;46:1288-94.
67. Myerburg R, Kessler K, Mallon S, et al. Lifethreatening ventricular arrhythmias in patients with silent myocardial ischemia due to coronaryartery spasm. N Engl J Med. 1992;326:1451-5.
68. Wolfe CL, Nibbley C, Bhandari A, Chatterjee K, Scheinman MM. Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation. 1991;84:1543-51.
69. Kakishita M, Kurita T, Matsuo K, et al. Mode of onset of ventricularfibrillation in patients with Brugada syndrome detected by implantable cardioverter defibrillator therapy. J Am Coll Cardiol. 2000;36:1646-53.
70. Chattha IS, Sy RW, Yee R, et al. Utility of the recovery electrocardiogram after exercise: a novel indicator for the diagnosis and genotyping of long QT syndrome? Heart Rhythm. 2010;7: 906-11.
71. Krahn AD, Klein GJ, Yee R. Hysteresis of the RT interval with exercise: a new marker for the long-QT syndrome? Circulation. 1997;96:1551-6.
72. Sy RW, van der Werf C, Chattha IS, et al. Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands. Circulation. 2011;124(20):2187-94.
73. Viskin S, Postema PG, Bhuiyan ZA, et al. The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome. J Am Coll Cardiol. 2010;55:1955-61.
74. Hong K, Brugada J, Oliva A, et al. Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. Circulation. 2004;110:3023-7.
75. Wolpert C, Echternach C, Veltmann C, et al. Intravenous drug challenge usingflecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm. 2005;2:254-60.
76. Ackerman MJ, Khositseth A, Tester DJ, Hejlik JB, Shen WK, Porter CB. Epinephrine-induced QT interval prolongation: a gene-specific paradoxical response in congenital long QT syndrome. Mayo Clin Proc. 2002;77:413-21.
77. Shimizu W, Noda T, Takaki H, et al. Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. J Am Coll Cardiol. 2003;41:633-42.
78. Garratt CJ, Antoniou A, Griffith MJ, Ward DE, Camm AJ. Use of intravenous adenosine in sinus rhythm as a diagnostic test for latent preexcitation. Am J Cardiol. 1990;65:868-73.
79. Varnava AM, Elliott PM, Baboonian C, Davison F, Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation. 2001;104:1380-4.
80. Varnava A, Baboonian C, Davison F, et al. A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy. Heart. 1999;82:621-4.
81. Fontaine G, Fornes P, Herbert JL. Ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathies. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology: from cell to bedside. 3rd ed. Philadelphia: W.B. Saunders; 2003.
82. Deantonio HJ, Kaul S, Lerman BB. Reversible myocardial depression in survivors of cardiac arrest. Pacing Clin Electrophysiol. 1990;13: 982-5.
83. Viskin S, Halkin A, Olgin JE. Treatable causes of sudden death: not really "treatable" or not really the cause? J Am Coll Cardiol. 2001;38:1725-7.
84. Brembilla-Perrot B, Terrier de la Chaise A, Isaaz K, Marcon F, Cherrier F, Pernot C. Inducible multiform ventricular tachycardia in Wolff-Parkinson-White syndrome. Br Heart J. 1987;58:89-95.
85. Wang Y, Griffin J, Lesh M, Cohen T, Chien W, Scheinman M. Patients with supraventricular tachycardia presenting with aborted sudden death: incidence, mechanism and long-term follow-up. J Am Coll Cardiol. 1991;18:1720-1.
86. Tester DJ, Kopplin LJ, Will ML, Ackerman MJ. Spectrum and prevalence of cardiac ryanodine receptor (RyR2) mutations in a cohort of unrelated patients referred explicitly for long QT syndrome genetic testing. Heart Rhythm. 2005;2:1099-105.
87. Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 2009;119:2426-34.
88. Nof E, Belhassen B, Arad M, et al. Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. Heart Rhythm. 2011;8:1546-52.
89. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long QT syndrome. N Engl J Med. 1992;327:846-52.
90. Hong K, Bjerregaard P, Gussak I, Brugada R. Short QT syndrome and atrialfibrillation caused by mutation in KCNH2. J Cardiovasc Electrophysiol. 2005;16:394-6.
91. Priori SG, Pandit SV, Rivolta I, et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res. 2005;96:800-7.
92. Bellocq C, van Ginneken AC, Bezzina CR, et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation. 2004;109: 2394-7.
93. Borggrefe M, Wolpert C, Antzelevitch C, et al. Short QT syndrome. Genotype-phenotype correlations. J Electrocardiol. 2005;38:75-80.
94. Belhassen B. A 25-year control of idiopathic ventricularfibrillation with electrophysiologicguided antiarrhythmic drug therapy. Heart Rhythm. 2004;1:352-4.
95. Wolpert C, Schimpf R, Giustetto C, et al. Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005;16:54-8.
96. Schimpf R, Wolpert C, Bianchi F, et al. Congenital short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery. J Cardiovasc Electrophysiol. 2003;14:1273-7.
97. Strohmer B, Schernthaner C, Pichler M. T-wave oversensing by an implantable cardioverter defibrillator after successful ablation of idiopathic ventricularfibrillation. Pacing Clin Electrophysiol. 2006;29:431-5.
98. Remme CA, Wever EF, Wilde AA, Derksen R, Hauer RN. Diagnosis and long-term follow-up of the Brugada syndrome in patients with idiopathic ventricularfibrillation. Eur Heart J. 2001;22:400-9
99. Shimizu W, Matsuo K, Takagi M, et al. Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: clinical implication of eighty-seven-lead body surface potential mapping and its application to twelvelead electrocardiograms. J Cardiovasc Electrophysiol. 2000;11:396-404.
100. Shimeno K, Takagi M, Maeda K, Tatsumi H, Doi A, Yoshiyama M. Usefulness of multichannel holter ECG recording in the third intercostal space for detecting type 1 brugada ECG: comparison with repeated 12-lead ECGs. J Cardiovasc Electrophysiol. 2009;20(9):1026-31.
101. Sangwatanaroj S, Prechawat S, Sunsaneewitayakul B, Sitthisook S, Tosukhowong P, Tungsanga K. New electrocardiographic leads and the procainamide test for the detection of the Brugada sign in sudden unexplained death syndrome survivors and their relatives. Eur Heart J. 2001;22: 2290-6.
102. Viskin S, Antzelevitch C. The cardiologists' worst nightmare sudden death from "benign" ventricular arrhythmias. J Am Coll Cardiol. 2005;46: 1295-7.
103. Shimizu W. Arrhythmias originating from the right ventricular outflow tract: how to distinguish "malignant" from "benign"? Heart Rhythm. 2009;6:1507-11.
104. Wever EFD, Hauer RNW, Oomen A, Peters RHJ, Bakker PFA, Robles de Medina EO. Unfavorable outcome in patients with primary electrical disease who survived an episode of ventricularfibrillation. Circulation. 1993;88:1021-9.
105. Moe T. Morgagni-Adams-Stokes attacks caused by transient recurrent ventricularfibrillation in a patient without apparent heart disease. Am Heart J. 1949;37:811-18.
106. Konty F, Dale J. Self-terminating idiopathic ventricularfibrillation presenting as syncope: a 40-year follow-up report. J Intern Med. 1990; 227:211-13.
107. Belhassen B, Viskin S. Management of idiopathic ventricular fibrillation: implantable defibrillators? antiarrhythmic drugs? ANE. 1998;3:125-8.
108. Belhassen B, Glick A, Viskin S. Ef ficacy of quinidine in high-risk patients with Brugada syndrome. Circulation. 2004;110:1731-7.
109. Belhassen B, Shapira I, Sheps D, Shoshani D, Laniado S. Programmed ventricular stimulation using up to two extrastimuli and repetition of double extrastimulation for induction of ventricular tachycardia: A new highly sensitive and specific protocol. Am J Cardiol. 1990;65: 615-22.
110. Belhassen B, Glick A, Viskin S. Excellent longterm reproducibility of the electrophysiologic efficacy of quinidine in patients with idiopathic ventricularfibrillation and Brugada syndrome. Pacing Clin Electrophysiol. 2009;32: 294-301.
111. Haghjoo M, Arya A, Heidari A, Sadr-Ameli MA. Suppression of electrical storm by oral quinidine in a patient with Brugada syndrome. J Cardiovasc Electrophysiol. 2005;16:674.
112. Marquez MF, Rivera J, Hermosillo AG, et al. Arrhythmic storm responsive to quinidine in a patient with Brugada syndrome and vasovagal syncope. Pacing Clin Electrophysiol. 2005;28: 870-3.
113. Marquez MF, Salica G, Hermosillo AG, et al. Ionic basis of pharmacological therapy in Brugada syndrome. J Cardiovasc Electrophysiol. 2007;18: 234-40.
114. Aizawa Y, Tamura M, Chinushi M, et al. An attempt at electrical catheter ablation of the arrhythmogenic area in idiopathic ventricularfibrillation. Am Heart J. 1992;123:257-60.
115. Kusano KF, Yamamoto M, Emori T, Morita H, Ohe T. Successful catheter ablation in a patient with polymorphic ventricular tachycardia. J Cardiovasc Electrophysiol. 2000;11:682-5.
116. Knecht S, Sacher F, Wright M, et al. Long-term follow-up of idiopathic ventricularfibrillation ablation: a multicenter study. J Am Coll Cardiol. 2009;54:522-8.
117. The Antiarrhythmic Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576-83.
118. Kron J, Herre J, Renfroe EG, et al. Lead-and device-related complications in the antiarrhythmics versus implantable defibrillators trial. Am Heart J. 2001;141:92-8.
119. Sacher F, Probst V, Iesaka Y, et al. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study. Circulation. 2006;114:2317-24.